Salud financiera de hoja de balance de Humacyte

Salud financiera controles de criterios 2/6

Humacyte tiene un patrimonio de los accionistas total de $-63.7M y una deuda total de $62.4M, lo que sitúa su ratio deuda-patrimonio en -97.9%. Sus activos y pasivos totales son $114.8M y $178.5M respectivamente.

Información clave

-97.9%

Ratio deuda-patrimonio

US$62.37m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$20.57m
Patrimonio	-US$63.72m
Total pasivo	US$178.49m
Activos totales	US$114.76m

Actualizaciones recientes sobre salud financiera

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Aug 16

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14

Análisis de la situación financiera

Pasivos a corto plazo: HUMA tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: HUMA tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: HUMA tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: HUMA tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: HUMA tiene suficiente cash runway para 3 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que HUMA disponga de suficiente cash runway para 4 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Humacyte

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Recent updates

Humacyte, Inc. Announces Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injury Published in Jama Surgery

Holzer & Holzer, LLC Files Class Action Lawsuit Against Humacyte, Inc

Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV™? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024

Consensus revenue estimates fall by 32%

Humacyte, Inc. has filed a Follow-on Equity Offering.

New minor risk - Profitability

Forecast to breakeven in 2026

Humacyte, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 Av Access Clinical Trial At the American Society of Nephrology’S Kidney Week 2024

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Humacyte, Inc. Announces Allowance of U.S. Patent Covering BioVascular Pancreas

Price target increased by 20% to US$13.17

Key Executive notifies of intention to sell stock

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

New minor risk - Insider selling

Humacyte, Inc. Acellular Tissue Engineered Vessel Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Price target increased by 13% to US$9.30

Consensus revenue estimates increase by 13%

Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors

High number of new directors

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week